Table 4.
Clinicopathological characteristics of patients with different treatment regimens
| Variables (n, %) | pT1N1 (n = 109) |
pT1N2 (n = 23) |
pT1N3 (n = 19) |
||||||
|---|---|---|---|---|---|---|---|---|---|
| OBS (n = 46) | ACT (n = 63) | P | S-1 (n = 11) | Xelox (n = 12) | P | S-1 (n = 7) | Xelox (n = 12) | P | |
| Age (years) | 0.639 | 0.51 | 0.044* | ||||||
| < 60 | 24 (52.2) | 30 (47.6) | 7 (63.6) | 6 (50.0) | 7 (100) | 6 (50.0) | |||
| ≥ 60 | 22 (47.8) | 33 (52.4) | 4 (36.4) | 6 (50.0) | 0 | 6 (50.0) | |||
| Gender | 0.735 | 0.214 | 0.656 | ||||||
| Male | 27 (58.7) | 39 (61.9) | 5 (45.5) | 9 (75.0) | 2 (28.6) | 5 (41.7) | |||
| Female | 19 (41.3) | 24 (38.1) | 6 (54.5) | 3 (25.0) | 5 (71.4) | 7 (58.3) | |||
| Tumor size (cm) | 0.92 | 0.059 | 0.96 | ||||||
| ≤ 2 | 26 (56.5) | 35 (55.6) | 8 (72.7) | 4 (33.3) | 4 (57.1) | 7 (58.3) | |||
| > 2 | 20 (43.5) | 28 (44.4) | 3 (27.3) | 8 (66.7) | 3 (42.9) | 5 (41.7) | |||
| Tumor location | 0.334 | 0.775 | 0.731 | ||||||
| Upper | 2 (4.3) | 4 (6.3) | 2 (18.2) | 1 (8.3) | 0 | 1 (8.3) | |||
| Middle | 10 (21.7) | 21 (33.3) | 3 (27.3) | 4 (33.3) | 3 (42.9) | 5 (41.7) | |||
| Lower | 34 (73.9) | 38 (60.3) | 6 (54.5) | 7 (58.3) | 4 (57.1) | 6 (50.0) | |||
| Gross type | 0.177 | 0.4 | 0.35 | ||||||
| Ulcerated | 21 (45.7) | 37 (58.7) | 3 (27.3) | 6 (50.0) | 2 (28.6) | 7 (58.3) | |||
| Non-ulcerated | 25 (54.3) | 26 (41.3) | 8 (72.7) | 6 (50.0) | 5 (71.4) | 5 (41.7) | |||
| Differentiation | 0.302 | 0.155 | 0.433 | ||||||
| Differentiated | 6 (13.0) | 13 (20.6) | 1 (9.1) | 5 (41.7) | 0 | 1 (8.3) | |||
| Undifferentiated | 40 (87.0) | 50 (79.4) | 10 (90.9) | 7 (58.3) | 7 (100) | 11 (91.7) | |||
| Histopathology | 0.63 | 0.116 | 0.432 | ||||||
| Tub | 6 (13.0) | 13 (20.6) | 1 (9.1) | 5 (41.7) | 0 | 1 (8.3) | |||
| Por | 32 (69.6) | 42 (66.7) | 8 (72.7) | 6 (50.0) | 6 (85.7) | 7 (58.3) | |||
| Sig | 6 (13.0) | 7 (11.1) | 2 (18.2) | 0 | 1 (14.3) | 4 (33.3) | |||
| Muc | 2 (4.3) | 1 (1.6) | 0 | 1 (8.3) | 0 | 0 | |||
| Examined lymph node | 21 (17,29) | 22 (18,34) | 0.232 | 27 (19,31) | 28 (21,35) | 0.487 | 30 (19,34) | 30 (17,43) | 0.902 |
| Her-2 status | 0.061 | 0.901 | 0.683 | ||||||
| Negative | 43 (93.5) | 51 (81.0) | 8 (72.7) | 9 (75.0) | 6 (85.7) | 11 (91.7) | |||
| Positive | 3 (6.5) | 12 (19.0) | 3 (27.3) | 3 (25.0) | 1 (14.3) | 1 (8.3) | |||
| Depth of invasion | 0.889 | 0.052 | 0.433 | ||||||
| T1a | 10 (21.7) | 13 (20.6) | 3 (27.3) | 0 | 0 | 1 (8.3) | |||
| T1b | 36 (78.3) | 50 (79.4) | 8 (72.7) | 12 (100) | 7 (100) | 11 (91.7) | |||
| Lymphovascular invasion | 3 (6.5) | 11 (17.5) | 0.092 | 2 (18.2) | 5 (41.7) | 0.371 | 5 (71.4) | 5 (41.7) | 0.35 |
| Perineural invasion | 1 (2.2) | 1 (1.6) | 0.822 | 0 | 0 | 1 | 2 (28.6) | 2 (16.7) | 0.603 |
*P < 0.05 was considered statistically significant. Tub, tubular adenocarcinoma; Por, poorly differentiated adenocarcinoma; Sig, signet-ring cell carcinoma; Muc, mucinous adenocarcinoma; Pap, papillary adenocarcinoma; T1a, mucosal invasion; T1b, submucosal invasion; OBS, observation; ACT, adjuvant chemotherapy.